Trial Profile
Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2018 Status changed from recruiting to completed.
- 08 Jan 2015 New trial record